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Available online 9 May 2016Background: Few interventions directly compare equivalent calcium and vitamin D from dairy vs. supplements
on the same bone outcomes. The radioisotope calcium-41 (41Ca) holds promise as a tracer method to directly
measure changes in bone resorption with differing dietary interventions.
Objective:Using 41Ca tracermethodology, determine if 4 servings/day of dairy foods results in greater 41Ca reten-
tion than an equivalent amount of calcium and vitaminD from supplements. Secondary objectivewas to evaluate
the time course for the change in 41Ca retention.
Methods: In this crossover trial, postmenopausal women (n = 12) were dosed orally with 100 nCi of 41Ca and
after a 180 day equilibration period received dairy (4 servings/day of milk or yogurt; ~1300 mg calcium,
400 IU cholecalciferol (vitamin D3/day)) or supplement treatments (1200 mg calcium carbonate/day and
400 IU vitamin D3/day) in random order. Treatments lasted 6 weeks separated by a 6 week washout (WO). Cal-
ciumwas extracted fromweekly 24 h urine collections; acceleratormass spectrometry (AMS)was used to deter-
mine the 41/40Ca ratio. Primary outcomewas change in 41/40Ca excretion. Secondary outcomewas the time course
for change in 41Ca excretion during intervention and WO periods.
Results: The 41/40Ca ratio decreased signiﬁcantly over time during both treatments; there was no difference be-
tween treatments. Both treatments demonstrated a signiﬁcant retention of 41Ca within 1–2 weeks (p =
0.0007 and p b 0.001 for dairy and supplements, respectively). WO demonstrated a signiﬁcant decrease (p =
0.0024) in 41Ca retention within 1–2 weeks, back to pre-intervention levels.
Conclusion: These data demonstrate that urinary 41Ca retention is increased with an increase in calcium and vi-
tamin D intake regardless of the source of calcium, and the increased retention occurs within 1–2 weeks.







Currently an estimated 10.2 million adults age 50 and older in the
United States have osteoporosis, while an estimated 43.5 million have
low bone mass (Wright et al., 2014). Health care costs related to osteo-
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ss article under the CC BY-NC-ND lice(Cosman et al., 2014). Calcium and vitamin D are widely considered the
most critical nutrients for osteoporosis prevention and treatment
(Caroli et al., 2011). Calcium absorption in the small intestine declines
with age, and women lose approximately 200 mg of calcium per day
in the ﬁrst 3–4 years of menopause, followed by approximately 45 mg
lost per day in the next 5–10 years (Tella and Gallagher, 2014). Calcium
can be lost in the feces, urine, skin, hair, nails, and digestive secretions
(Bauer, 2013; Heaney, 2000).
Many population groups in theWest fall short of the recommended
dietary calcium intake, particularly postmenopausal women (Peters
and Martini, 2010). The Institute of Medicine now recommends
1200 mg of calcium per day for women 51 years and older (Institute
of Medicine (US), 2011), but average intakes for American women are
estimated to be 750–850 mg of calcium per day (Bauer, 2013). Calcium
supplement use is common: nearly 60% of women in the US take a cal-
cium supplement (Moyer and Vitamin, 2013). Evidence to support the
use of calcium and/or vitamin D supplements for fracture preventionnse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014). In light of the numerous concerns related to calcium supple-
ments, nutrition experts frequently encourage patients to consume cal-
ciumvia food, especially dairy products (Moyer andVitamin, 2013). The
2015-2020 Dietary Guidelines for Americans recommend three cups of
low fat or fat free milk (or equivalent dairy products) per day for bone
health in persons nine years old and above (US Department of Health
andHuman Services and US Department of Agriculture). Some observa-
tional studies have shown no positive effects of dairy intake on bone in
older adults (Feskanich et al., 2003; Wadolowska et al., 2013;
Michaelsson et al., 2014). In contrast, other observational studies sup-
port a beneﬁt of dairy products on bone health (Key et al., 2007; Sahni
et al., 2014).
Randomized controlled trials (RCT) using dairy foods have reported
a beneﬁcial impact on markers of bone turnover (Heaney et al., 2002;
Bonjour et al., 2008) as well as on bone mineral density (BMD) (Chee
et al., 2003; Moschonis et al., 2010) in postmenopausal women, but
very limited work has compared equivalent amounts of calcium from
dairy foods vs. supplements on the same bone outcome variables
(Recker and Heaney, 1985; Prince et al., 1995; Manios et al., 2007).
Current methods of assessing bone health have limitations. Dual en-
ergy X-ray absorptiometry (DXA) is used clinically tomonitor BMD, but
is limited by low sensitivity as well as the inability to capture all aspects
of bone strength. Image quality and spatial resolution of the scans are
poor, and six months to two years are required to detect signiﬁcant
changes in BMD after an intervention. Quantitative computed tomogra-
phy (qCT) scans of bone,whichmeasure volumetric BMD, aremore sen-
sitive and precise than DXA, but expose subjects to a greater radiation
dose (Beck, 2003). Biomarkers of bone turnover can be measured to as-
sess bone remodeling rates. Although biomarkers of bone turnover re-
quire less time than imaging techniques to see the effects of an
intervention, they are limited by high inter- and intra-individual varia-
tion (Civitelli et al., 2009).
The radioisotope 41calcium (41Ca), in conjunction with accelerator
mass spectrometry (AMS), holds promise as a technique to measure
small changes in calcium retention in a short period of time. In brief, cal-
cium kinetic studies can be done tomonitor appearance and disappear-
ance of the tracer in a variety of biological specimens (Lin et al., 2004).
These techniques reveal changes in bone accretion and resorption in re-
sponse to experimental interventions. Because bone turnover is slow
the 41Ca isotope can be used in vivo to deep label the skeleton. The
41Ca isotope has a half-life of 1.03 × 105 years, negligible radiological
risk to human and can be used to assess short term changes in 41Ca re-
tention with a variety of interventions following a single small dose
(Civitelli et al., 2009; Lin et al., 2004). Following an oral dose, the 41Ca
tracer is taken up into a short-term pool where it awaits incorporation
into the skeleton. The tracer not incorporated into the skeleton is grad-
ually excreted from the short-term pool into urine; this takes approxi-
mately 6 months (Denk et al., 2006). After the 6 month equilibration
period any tracer in the body resides in mineralized bone, and the ap-
pearance of 41Ca in urine is a direct result of bone turnover (41Ca
being lost from the skeleton). The amount of 41Ca lost from the skeleton
is evaluated by comparing the tracer excretion curve extrapolated from
equilibration data prior to intervention to the tracer excretion curve
during intervention (Denk et al., 2007; Fitzgerald et al., 2005). In addi-
tion, subjects can also serve as their own controls in crossover studies,
so smaller sample sizes can be used (Denk et al., 2007). To date, this
method has not been employed in a nutritional intervention with
dairy foods.2. Aims
The aims of this studywere to 1) determine if 4 servings/day of dairy
foods increase 41Ca retention more than an equivalent amount of calci-
um& vitamin D from supplements. Secondary objectivewas to evaluatethe time course for change in 41Ca retention in healthy postmenopausal
women.3. Materials and methods
3.1. Subjects
A total of 12 healthy women at least two years post-menopause
completed the study protocol. Subjects ranged in age from 50 to
65 years, were weight stable (±2.3 kg in the past three months),
and were classiﬁed as low dairy consumers (≤2.5 serves/day). Ex-
clusion criteria included the use of oral hormone therapy in the
past year, BMD T scores N 0 or b−1.5, use of calcium or vitamin D
supplements, autoimmune or inﬂammatory disorders, history of
non-traumatic bone fracture, and lactose intolerance. Subjects
were recruited from the community via ﬂyers, newspaper ads,
and email list serves as well as informational booths at local
farmers' markets. The study was conducted at the USDA, Western
Human Nutrition Research Center (WHNRC) on the University of
California, Davis campus and was approved by the Institutional Re-
view Boards of the University of California, Davis (#22919-7) and
Lawrence Livermore National Laboratory (LLNL) (#11-008). A
CONSORT diagram of enrollment and follow up of study subjects
is shown in Fig. 1. All study participants gave informed consent
prior to starting the study protocol. The study was registered at
clinicaltrials.gov as NCT01394484.3.2. Study design
The study design is summarized in Fig. 2. After enrollment, sub-
jects received an oral labeling dose of 100 nCi 41Ca and began a
180 day equilibration period during which the isotope excretion
stabilized to a steady rate of natural loss. Subjects were instructed
to continue their normal low dairy diet and lifestyle during this
time. Subjects provided 24 h urine collections prior to the 41Ca
dose (day 0), and during the equilibration period at days 90, 120,
150, and 180.
Following the 180 day equilibration period subjects were random-
ized to one of two 42 day interventions followed by a 42 day washout
(WO)period. After completion of the initial intervention andWOperiod
women continued the study on the second intervention. The dairy in-
tervention included 20 (1 cup/237 mL) servings of milk (1% fat,
400 mg calcium and 100 International Units (IU) cholecalciferol (vita-
min D3)/serving) per week and 8 (8 oz./227 g) servings of yogurt (low
fat vanilla, 200 mg calcium and 100 IU vitamin D3 per serving) per
week. Women were instructed to consume the dairy foods throughout
the day. Supplement intervention included a calcium supplement tablet
(600 mg calcium per tablet; Caltrate) twice daily and a vitamin D sup-
plement tablet (400 IU vitamin D3 per tablet) once daily. No other sup-
plements were permitted.
Dairy provided ~1300 mg calcium and 400 IU vitamin D3/day, and
supplements provided 1200 mg calcium and 400 IU vitamin D3/day.
Subjects were instructed by the study dietitian how to adjust their
food intake to account for the energy associated with the dairy servings
(~350 kcal per day) and where dairy foods could be included in their
diets, e.g. coffee latte for 1 serving of milk. Subjects were instructed to
follow their usual (low dairy diet) during the supplement and WO
periods.
Subjects completed 24 h urine collections for the measurement
of the excreted 41Ca, as well as other urinary minerals. Urine collec-
tions were made at the beginning and at weekly intervals for each
intervention and WO phase; for a total of 24 (24 h) urine collec-
tions. Blood was drawn at ~0800, following an overnight fast of
10 h, at the beginning and end of each intervention period.
Fig. 1. Enrollment and follow up of participants in the randomized crossover trial.
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During the intervention periods, subjects reported to the WHNRC
weekly to pick up the dairy products or supplement tablets. Compliance
to the interventions was measured via empty milk and yogurt con-
tainers that were returned and by pill count on returned supplement
foil-blister packs. Additionally, diet records were kept and reviewedFig. 2. Study design. After enrollment, women received a minute labeling dose of 41calcium,
randomly assigned to either the dairy or supplement interventions for 42 days. After a 42 dayfor compliance by the study dietitian weekly when women returned
to the WHNRC to pick dairy or supplement supplies.
3.4. Dietary assessment
Women kept 3-day food logs each week for each intervention and
the WO period. The ﬁrst day of the ﬁrst diet record was randomlywhich was incorporated into the skeleton over a period of 180 days. Women were then
WO period, subjects completed the second intervention for 42 days.
120 T.S. Rogers et al. / Bone Reports 5 (2016) 117–123assigned, and thereafter the days of the week progressed sequentially.
For example, day 1 diet record might start on aWednesday and contin-
ue through Friday of week 1. The diet record for the secondweek of the
intervention would then start on Saturday and continue through Monday.
This “rolling” sequence was continued throughout the entire protocol.
This provided an equal number of records for each day of the week for
the course of the study; a total of 8 days for each day of the week: 8 Sun-
days, 8Mondays, 8 Tuesdays, etc. for a total of 56 days. During the dairy in-
tervention,women also recorded the number of servings they consumedof
the milk and yogurt provided each day, as well as other dairy foods con-
sumed. During the supplement intervention women recorded their daily
supplement consumption in their diet log. In addition, women were
interviewed by a registered dietitian to verify their food records.
The Nutrition Data System for Research (NDSR, University of Minne-
sota, 2011)was used to analyze the diet records for energy, macronutri-
ents, calcium, phosphorus, magnesium, sodium, potassium, saturated
fat, monounsaturated fat, polyunsaturated fat, trans fat, vitamin D, and
servings of dairy, fruit, vegetables, grains, meat, nuts and seeds.
3.5. Anthropometric measurements
Anthropometric measurements were taken for each woman by a
trained research assistant. Body weight was measured to the nearest
0.1 kg using an electronic scale (Circuits and Systems Inc., E. Rockaway,
NY). Standing height, without shoes, was measured to the nearest
0.1 cm with a wall-mounted stadiometer (Ayrton stadiometer, model
S100; Ayrton Corp, Prior Lake, MN). Body mass index (BMI) was calcu-
lated based on weight and standing height measurements and
expressed as kg/m2.
3.6. Body composition and bone mineral density
Body composition (leanmass and fatmass of the total body) aswell as
bone mineral content (BMC), and areal BMD of the lumbar spine and hip
were measured with a Delphi-W QDR DXA bone densitometer (Hologic
Inc., Bedford, MA). Calibration procedures were carried out daily accord-
ing to manufacturer instructions. The coefﬁcient of variation (CV) for the
DXA instrument during the course of the studywas 0.457% for the lumbar
spine BMD calibration phantom. All DXA scans were analyzed by a single
operator to decrease the variance in the measurement data.
3.7. Accelerator mass spectrometry: measurement of 41Ca
Calcium was extracted from each of the 24 h urines collected and
used to determine the 41/40Ca ratio. The calcium extraction for the
41Ca tracer has been previously described (Lin et al., 2004). Brieﬂy, sam-
ples were converted to acid solution with HCl to pH b 1.9. Acid soluble
calcium from the 14 urine samples was converted to calcium oxalate
by adding saturated ammonium oxalate solution. Concentrated ammo-
nium hydroxide (NH4OH) was used to adjust the samples to pH 10 and
thus promote the release of less soluble metal oxalates. The oxalate pel-
let was re-suspended in acid, and calcium was isolated from other
cations using cation exchange chromatography. Concentrated
hydroﬂuoric acid (28.9 molarity) was added to yield calcium ﬂuoride,
which was then pelletized by centrifugation and washed with de-ion-
ized water. Samples were dried at 100 °C for 20 h in a mufﬂe furnace.
Samples were shipped from the WHNRC to the LLNL (Livermore, CA).
A small amount of niobium powder (1 part Nb:4 parts CaF2 by mass)
was added to increase thermal and electrical conductivity for ion
beam stability in the AMS source. Primary isotopic standards, secondary
standards, and backgrounds were prepared at LLNL following previous-
ly described methods (Lin et al., 2004). Acidic solutions with known
41Ca/40Ca ratios were used to precipitate calcium ﬂuoride by the addi-
tion of concentrated hydroﬂuoric acid, followed by centrifugation, rins-
ing with de-ionized water, and drying overnight in a mufﬂe furnace at
100 °C. The use of the 40Ca in the 41Ca/40Ca standards is importantbecause it represents urinary calcium excretion from all sources, e.g. di-
etary intake, compared to the 41Ca whose only source, after equilibra-
tion, is from the skeleton. All samples and standards were analyzed on
the HVEE-FN-class AMS system at LLNL operated as described
(Fitzgerald et al., 2005). N88% of the normalized primary standards
werewithin 5% of the published value (Nishiizumi et al., 2000). Average
repeatability of the secondary standards was generally 1–7% for
41Ca/40Ca ranging 9 × 10−9 to 9 × 10−12.
3.8. Statistical analysis
Sample size calculation for the 12 subject studywas based on the as-
sumption that the change in the 41/40Ca ratio is not correlated within-
subjects and that the standard deviation of the change in the ratio is
10 percentage points and resulted in an 80% power to detect a 12.6%
change in urinary 41/40Ca over time.
The change in the 41/40Ca ratio was the primary outcome variable for
this study. Evaluation of the calcium loss was based on the 41/40Ca uri-
nary excretion from the weekly 24-h urine collections over the
6weeks of each intervention and theWO. Therefore, each period (inter-
vention andWO) had 6 urinary data points, one per week for the dura-
tion of the 6-week intervention. Data were coded for order effect (dairy
ﬁrst or supplements ﬁrst) and analyzed by analysis of variance
(ANOVA) to determine if an order effect existed. ANOVA was also
used to determine if signiﬁcant differences existed between dairy and
supplement interventions in the urinary 41/40Ca excretion over the 6-
week intervention (treatment by time interaction).
Continuous variables were assessed for normality using Shapiro-
Wilk and D'Agostino-Pearson normality tests and were transformed as
appropriate. Nonparametric tests were used on data that were not con-
ducive to transformation. Descriptive statistics were performed on
pre-41Ca dose baseline characteristics. The secondary outcome of time
to change in 41/40Ca was evaluated by ANOVA using the difference be-
tween weekly 41/40Ca values.
Additionally, to testwhether the 41/40Ca excretion ratiowas different
fromwhat would be expected in the case of no intervention the kinetic
model developed by Denk et al. (Denk et al., 2006)was used to establish
the predicted curve of 41Ca loss from the 41Ca excretion data during the
180 equilibration period plus the values during the WO. The actual
values during the two interventions were compared to the predicted
values with a mixed model analysis that included type of measurement
(actual vs. predicted), intervention (dairy vs. supplement), week of in-
tervention (1 through 6), and period of intervention (ﬁrst vs. second)
and all of their estimable interactions as main effects, and subject as a
random effect. SAS for Windows Release 9.4 (SAS Institute, Inc., Cary,
NC) and GraphPad Prism 6.0c (GraphPad Software, Inc., La Jolla, CA)
were used for statistical analyses.
4. Results
Subject characteristics at baseline (prior to the 41Ca dose on day 0)
are shown in Table 1. All subjects were healthy postmenopausal
women with hip and spine bone densities at the low end of the normal
range. Compliance to treatment regimens was 100% for both phases.
The ratio of urinary 41/40Ca excretion over time for each treatment is
shown in Fig. 3. There was a signiﬁcant decline in the 41/40Ca excretion
during Intervention I compared to the predicted valuewith no interven-
tion. Conversely, therewas a signiﬁcant increase in the 41/40Ca excretion
duringWO returning to pre-intervention or untreated levels. During In-
tervention II the 41/40Ca excretion declined signiﬁcantly a second time.
The response to either Intervention or WO was observed within 1–
2 weeks and continued to decline throughout the 6 weeks with the
maximum reduction occurring by week 6 (Table 2; Fig. 3). The urinary
41Ca excretion decreased during both interventions, conﬁrming a fast-
exchangeable pool suggested in kinetic models (Denk et al., 2007;
Wastney et al., 1996). During WO the excretion increased also within
Table 1
Subject characteristics at baseline (n = 12 females).
Parameter Mean ± Standard deviation
Age (years) 55.4 ± 2.5
Height (cm) 163.0 ± 4.9
Weight (kg) 63.9 ± 8.5
BMI (kg/m2) 24.2 ± 3.7
Body fat (%) 38.0 ± 7.4
Fat-free mass (kg) 37.2 ± 3.2
Spine BMC (g) 45.6 ± 4.1
Spine BMD (g/cm2) 1.1 ± 0.1
Spine T-Score −0.82 ± 0.62
Hip BMC (g)a 27.0 ± 2.4
Hip BMD (g/cm2)a 0.9 ± 0.1
Hip T-Scorea −0.88 ± 0.06
Systolic blood pressure (mm Hg) 117 ± 21
Diastolic blood pressure (mm Hg) 75 ± 14
PTH (pmol/L) 59 ± 19
a Average of right and left hip values.
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return to “normal” pre-intervention levels of excretion (Table 2). Re-
peated measures ANOVA revealed a signiﬁcant time effect during both
intervention periods and theWO in the 41/40 Ca ratio response to treat-
ment or WO (Table 2).
Typicalwith increased calcium intake is increased calciumexcretion,
this study was no different. Dietary calcium increased ~170% and uri-
nary calcium was elevated during the intervention periods (179 ±
59mg vs. 150± 60mg) compared to the value just before the interven-
tion (Fig. 4). This translates to a 20.7% increase in urinary calciumduring
interventions and only a small portion of the increased calcium intake.
However, the change in 41Ca was not entirely explained by the in-
creased total urinary excretion and a possible dilution effect. Fig. 4
also shows that during weeks 3, 4, 5, and 6 urinary Ca trends back to-
ward pre-intervention levels from a high of about 21% at week 2 to
just 6% at week 6. This may be interpreted as the body adjusting to
the increased Ca load. 41/40Ca duringweeks 3–6 show amuchmore sta-
ble trend dropping from −16% at week 2 to −19% at week 6; a 3%
higher 41Ca retention in bone pools by the end of the ﬁrst intervention.
Results for the second intervention were not different from those ob-
served in the ﬁrst intervention. The 3% observed retention in 41Ca
could be due to either decreased resorption or increased formation.
Given that both dairy and supplement interventions demonstrated no
change in BAP (bone alkaline phosphatase), but did show a decrease
in CTx (carboxy-terminal collagen crosslinks) (Supplemental Table 2),
we suggest that the observed 41Ca retention was most likely due to de-
creased resorption.Fig. 3. 41/40Ca excretion ratio over time (n = 12) for each intervention period and WO.
Signiﬁcant differences were observed by week 1 of each intervention periods I, II and
wash out (0.0007, 0.0056, b0.0001, respectively).5. Discussion
Bymeasuring the change in 41/40Ca in urine by AMSwehave demon-
strated that interventions using calciumand vitaminD from either dairy
foods or supplements exert equal effects on calcium metabolism. Fur-
thermore, our study is the ﬁrst to show that the rapid turn-over pool
suggested in calcium kinetic model literature (Wastney et al., 1996) is
responsive to a calcium and vitamin D intervention, whether from
food or supplements, as quickly as one week.
The 41Ca-AMS method has been used to assess the effect of
bisphosphonates in postmenopausal women (Denk et al., 2007), in a
comparison of healthy vs. end stage renal disease patients (Fitzgerald
et al., 2005) as well as in a comparison of different isoﬂavone sources
in postmenopausal women (Wastney et al., 1996). The present study
is theﬁrst to utilize the 41Ca isotopewith AMS quantiﬁcation in an inter-
ventionwith dairy foods vs. supplements. Denk and colleagues (Denk et
al., 2007), in a study using bisphosphonates with postmenopausal
women, present a 3-compartment kinetic model similar to that of
Wastney et al. (Wastney et al., 1996) in adolescent girls and young
women. In both studies the authors indicate that compartment 2, the
fast exchange pool, serves as a transfer station to deposit into or remove
calcium from a slower turnover pool – presumably the skeleton.
Wastney and coauthors provide kinetic details, after oral and intrave-
nous administration of calcium isotopes, in serum, urine and feces in ad-
olescent girls compared to young women and demonstrated higher
rates of absorption, lower rates of excretion, higher turnover of bone
and higher calcium retention in the girls vs. the young women. They
did not conduct an intervention to determine responsiveness in the rap-
idly exchanging compartment 2 to calcium and vitamin D use.
Denk and colleagues (Denk et al., 2007) examined changes in calci-
um kinetics to bisphosphonates therapy, not dietary or supplement cal-
cium and vitaminD, andonly analyzed urinary 41/40Ca ratio at 2, 4, 6 and
8 weeks after administration and monthly thereafter. The urine collec-
tions at these intervals did not allow for the examination of the shorter
more responsive fast turn-over pool.
Schild et al. (Schild et al., 2015) also using 41Ca labeling method
found that urinary 41Ca retention was increased with increasing levels
of daily vitamin D supplementation taken daily for 3months by healthy
postmenopausal women. Supplementation was positively associated
with a downward shift in the urinary 41/40Ca ratio compared to the pre-
dicted changewithout intervention. Schild et al. also demonstrated that
increasing levels of vitamin D affected the transfer rate from the central
compartment to a fast exchange compartment. They hypothesized that
the fast exchange compartment represented an exchange from the ex-
tracellular space to the surface of the bone. Our results also demonstrate
the rapidity with which the fast exchangeable pool responds to in-
creases or decreases in calcium and vitamin D intake.
Our ﬁndings of no difference in calcium retention between food vs.
supplemental intake of calcium and vitamin D is in contrast with
those of Recker and Heaney (Recker and Heaney, 1985) who reported
that both a low-fat milk and calcium carbonate supplement improved
calciumbalance in 30 healthy postmenopausalwomen, but calciumcar-
bonate suppressed bone remodeling to a greater extent thanmilk. How-
ever, this conclusion was based on data from two separate studies and
was, therefore, not a direct comparison.
More consistent with the present ﬁndings were those of Prince and
colleagues (Prince et al., 1995), who conducted a two-year study of
168 postmenopausal women and evaluated the effects three different
calcium treatments or placebo on BMD. Calcium lactate gluconate tab-
lets and skim milk powder signiﬁcantly attenuated bone loss at certain
sites (inter-trochanteric hip, ultradistal tibia) compared to placebo, but
differences between these treatments were not signiﬁcant. The investi-
gators concluded that the milk powder and calcium carbonate were es-
sentially equivalent in preventing bone loss (Prince et al., 1995). Later,
Manios et al. (Manios et al., 2007) reported a 12month RCT of 101 post-
menopausal Greekwomen and compared three servings of low fat dairy
Table 2
Change in 41/40 Ca excretion during intervention and wash out periods.
Days–Week N Mean Standard deviation Probability
Intervention - I
187 – week 1 12 −0.157 0.166 0.0007
194 – week 2 12 −0.271 0.0922 b0.0001
201 – week 3 12 −0.299 0.136 b0.0001
208 – week 4 12 −0.356 0.117 b0.0001
215 – week 5 12 −0.411 0.137 b0.0001
222 – week 6 12 −0.418 0.132 b0.0001
Wash Out
229 – week 1 12 0.116 0.103 0.0024
236 – week 2 12 0.168 0.126 0.0007
243 – week 3 12 0.153 0.112 0.0006
250 – week 4 12 0.134 0.0931 0.0004
257 – week 5 12 0.187 0.133 0.0005
264 – week 6 12 0.176 0.122 0.0004
Intervention – II
271 – week 1 12 −0.155 0.072 b0.0001
278 – week 2 12 −0.210 0.123 0.0002
285 – week 3 12 −0.250 0.0984 b0.0001
292 – week 4 12 −0.315 0.0929 b0.0001
299 – week 5 12 −0.315 0.124 b0.0001
306 – week 6 12 −0.326 0.133 b0.0001
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the three groups, dairy consumption led to the greatest attenuation of
bone resorption (a 23% decrease in CTx). Unlike our study, the dairy
group had signiﬁcantly greater BMD at the pelvis, total spine and total
body after 12 months compared to the supplement and control groups,
suggesting an advantage of dairy treatment on multiple parameters of
bone health (Manios et al., 2007).
Neither the present study nor the study by Prince and colleagues
(Prince et al., 1995) showed robust differences in the anti-resorptive ef-
fects of the calcium supplement versus dairy foods, but advantages of
dairy become evident when dietary intake data are examined. In the
present study, subjects consumed signiﬁcantly greater amounts of pro-
tein, carbohydrate, vitaminA, zinc andpotassiumduring the dairy treat-
ment than during either the supplement intervention or WO
(Supplemental Table 1). The dairy intervention also led to signiﬁcantFig. 4.Weekly least-square means for urinary 40Ca,increases in dietary intake of folate, phosphorus, and magnesium com-
pared to the subjects' typical intake (WO). These nutrients are well rec-
ognized as bone-enhancing nutrients (Caroli et al., 2011; Peters and
Martini, 2010; Weaver, 2009) and, over a longer duration, may result
in a shift toward a signiﬁcant difference between food and supplement
treatments.
It is possible that the six week time frame of the present study was
too brief to observemineralization changes represented by bone forma-
tion markers such a bone alkaline phosphatase (BAP) (Supplemental
Table 2). The lack of change in BAP is consistent with a study of post-
menopausal women by Bonjour and colleagues (Bonjour et al., 2008).
This 16-week crossover trial compared treatment with 1200 mg/day
calcium from semi skimmedmilk vs. nomilk supplement and found sig-
niﬁcant changes in bone formationmarkers amino-terminal propeptide
of type 1 procollagen (P1NP) and osteocalcin, but not in BAP. Likewise,41Ca and the 41/40Ca ratio during interventions.
123T.S. Rogers et al. / Bone Reports 5 (2016) 117–123no signiﬁcant PTH change during either treatment is consistent with
previous reports that calcium intake prevents increases in PTH over
time (Chee et al., 2003; Manios et al., 2007). Calcium tablets have
been shown to signiﬁcantly decrease PTH after 6 months (Prince et al.,
1995), but the six week treatment duration in the present study may
have been insufﬁcient to observe this suppressive effect. The sample
size of the present study is comparable to other 41Ca-AMS studies by
Weaver and colleagues (Weaver, 2009) (n = 11) and Denk and col-
leagues (Denk et al., 2007) (n = 6). The crossover design allowed
eachwoman to serve as her own control, thereby limiting inter-individ-
ual variability and allowing for a smaller sample size.
A limitation of the present study is the racial homogeneity in this
sample of Caucasian women. Racial differences in bone density and
bone structure arewell known (Heaney, 2000), so results of the present
study cannot be extrapolated to other women of other races. An added
limitation of the present study is that the vitamin D3 dose of 400 IU/day
given during both treatments does not reﬂect the most current RDA
value of 600 IU per day for women 51–70 years old. The RDA changed
from 400 IU to 600 IU while the present study was underway
(Institute of Medicine (US), 2011), so we proceeded with the original
study protocol. Future studies using daily doses of vitamin D3 N 400 IU
are needed (Moyer and Vitamin, 2013).
The present study is the ﬁrst to use the 41Ca-AMS method in a die-
tary intervention studywith dairy products and directly compares calci-
um and vitamin D intake from dairy foods vs. supplements on the same
bone variables. The highly sensitive 41Ca-AMS technique represents an
alternative method to other methods like bone turnover biomarkers
that require large sample sizes and months of intervention to detect
treatment differences. Both dairy products and calcium vitamin D sup-
plements demonstrated comparable short term effect on calcium reten-
tion, but the dairy treatment provided a more nutrient dense diet for
this group of postmenopausal women.
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